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BACKGROUND: The National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse 
Events, collected alongside the clinician-reported Common Terminology Criteria for Adverse Events, enables comparisons of patient and 
clinician reports on treatment toxicity. METHODS: In a multisite study of women receiving chemotherapy for early-stage breast cancer, 
symptom reports were collected on the same day from patients and their clinicians for 17 symptoms; their data were not shared with 
each other. The proportions of moderate, severe, or very severe patient-reported symptom severity were compared with the propor-
tions of clinician-rated grade 2, 3, or 4 toxicity. Patient-clinician agreement was assessed via κ statistics. Chi-square tests investigated
whether patient characteristics were associated with patient-clinician agreement. RESULTS: Among 267 women, the median age was 
58 years (range, 24-83 years), and 26% were nonwhite. There was moderate scoring agreement (κ = 0.413-0.570) for 53% of symptoms,
fair agreement for 41% (κ = 0.220-0.378), and slight agreement for 6% (κ = 0.188). For example, patient-reported and clinician-rated per-
centages were 22% and 8% for severe or very severe fatigue, 41% and 46% for moderate fatigue, 32% and 39% for mild fatigue, and 6% 
and 7% for none. Clinician severity scores were lower for nonwhite patients in comparison with white patients for peripheral neuropathy, 
nausea, arthralgia, and dyspnea. CONCLUSIONS: Although clinician reporting of symptoms is common practice in oncology, there is 
suboptimal agreement with the gold standard of patient self-reporting. These data provide further evidence supporting the integration 
of patient-reported outcomes into oncological clinical research and clinical practice to improve monitoring of symptoms as well as timely 
interventions for symptoms. Cancer 2020;126:3084-3093. © 2020 American Cancer Society. 
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INTRODUCTION
The National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE)1 is the long-standing stan-
dard approach for the collection and reporting of adverse events in oncology research.2 Of the approximately 800 adverse 
events included in the CTCAE item library, approximately 10% correspond to symptoms, such as nausea and sensory 
neuropathy. However, CTCAE items are recorded by clinical research staff rather than patients. In response to growing 
evidence for the value of patient-reported symptom severity as a complement to clinician-assessed toxicity,3 the National 
Cancer Institute supported the development of the Patient-Reported Outcomes Version of the Common Terminology 
Criteria for Adverse Events (PRO-CTCAE),4,5 which became publicly available in April 2016. Like CTCAE, PRO-
CTCAE provides single-item measures for patient-reported symptom severity and also includes items for interference 
with usual or daily activities and the frequency of some symptoms.
The development of PRO-CTCAE held the promise of improved understanding of patient and clinician toxicity 
reports for multiple symptoms simultaneously and at multiple time points during chemotherapy if PRO-CTCAE 
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and CTCAE reports were completed in real time during 
the same clinic visit.6 This would enable more rigorous 
analyses of convergence and divergence in patient and 
clinician perspectives on important clinical endpoints 
such as quality of life and function.7 PRO-CTCAE 
could also facilitate collaborative reporting on symp-
toms that are not asked about routinely through a pro-
cess in which patient-reported toxicity forms are made 
readily available to the treating clinician during routine 
clinic visits.8
Within a growing body of literature documenting 
discrepancies between patient- and clinician-reported 
toxicities,8 studies making paired comparisons of health 
care provider–assessed CTCAE and patient-reported 
PRO-CTCAE (or patient-tested precursors to PRO-
CTCAE) have been conducted in patients receiving 
chemotherapy for head and neck cancer,9 genitourinary 
cancer,10 and lung cancer,10,11 patients receiving radio-
therapy,12 and patients receiving chemotherapy and/
or radiation therapy,5 with 4 of these studies collecting 
data at more than 1 time point during treatment.5,9,11,12 
Additional studies have compared CTCAE toxicity 
grades with validated symptom measures such as the 
European Organisation for the Research and Treatment 
of Cancer Core Quality of Life Questionnaire (QLQ-
C30)13-15 and other study-specific symptom reports,16 
with 1 of these studies collecting data at multiple time 
points during treatment.14 Some of the aforementioned 
studies included women with early breast cancer within 
a mixed sample of adults with cancer; however, find-
ings were not reported separately for each type of can-
cer5,13,16 or had a specific focus on early-stage breast 
cancer.
In this study, we conducted an analysis among 
women with early-stage breast cancer in which we com-
pared clinician-reported (CTCAE) and patient-reported 
(PRO-CTCAE) severity for 17 symptoms collected at 
multiple time points throughout chemotherapy. We 
have previously reported that patient-assessed symp-
tom severity for these 17 symptoms varies significantly 
among 4 chemotherapy regimens commonly used in 
current clinical practice,17 and this confirms the impor-
tance of continuous symptom monitoring throughout 
treatment. We have also reported that there is mini-
mal agreement between patient- and clinician-reported 
severity scores for chemotherapy-induced peripheral 
neuropathy associated with these chemotherapy regi-
mens.18 In the current study, we compare patient and 
clinician reports for all 17 symptoms, and we identify 




This is a secondary analysis of data from a sample of 
women recruited into 1 of 3 prospective, nonrandomized 
studies of a walking intervention for patients receiving 
(neo)adjuvant chemotherapy for early breast cancer 
(stages 0-III according to American Joint Committee 
on Cancer staging, 7th edition; ClinicalTrials.gov 
identifiers NCT02167932, NCT02328313, and 
NCT03761706). Patients were 21  years old or older 
and were recruited before starting chemotherapy regi-
mens that were selected by clinicians in consultation 
with their patients. Patients provided written informed 
consent, and the studies were approved by the University 
of North Carolina Lineberger Comprehensive Cancer 
Center’s protocol review committee and the institu-
tional review boards for each study site.
Measures
From chemotherapy initiation through the end of 
chemotherapy, patients completed a patient-reported 
symptom form for 17 symptoms. These symptoms 
were selected a priori for their observed frequency in 
the treatment of patients with early breast cancer. In 
2 studies (NCT02167932 and NCT02328313), the 
reporting form was the validated patient-reported symp-
tom monitor (PRSM).19 The PRSM was a precursor to 
PRO-CTCAE and was used because PRO-CTCAE was 
not publicly available when these 2 studies were initi-
ated. The PRSM precursor was developed by investi-
gators who were also involved with the development 
of PRO-CTCAE4,20 and has a structure and response 
scale analogous to those of PRO-CTCAE (Supporting 
Table 1); it uses single-item measures of symptom se-
verity on a 5-point scale with response options ranging 
from “none/no symptom” to “very severe.”21 In addi-
tion, using a single-item measure, patients reported 
the symptom “interference with doing things you usu-
ally do” with similar 5-point response options ranging 
from “not at all” to “very much.” When PRO-CTCAE 
became publicly available, it was used as the reporting 
form for the third study (NCT03761706). Depending 
on their chemotherapy infusion schedule over 4 to 8 
total cycles, patients completed symptom reports every 
other week or every third week. Patients with weekly 
infusion schedules (mostly paclitaxel) completed 
symptom reports every other week to avoid overreport-
ing in this cohort in comparison with the rest of the 
sample. Patients completed symptom reports during 
their chemotherapy infusion, which was after they had 
seen their oncology clinician.
On the same day that patients completed symptom 
reports, their oncology clinician (MD, nurse practitioner, 
or physician assistant) was asked to complete a CTCAE 
study form to rate the same set of 17 symptoms. The patient 
reports were not available to their clinicians. For compari-
son with patient-reported scores, CTCAE response options 
were standardized across symptoms as follows: 0 = none, 
1 = mild, 2 = moderate, 3 = severe, and 4 = disabling.22,23 
We matched patient-reported “none” with CTCAE grade 
0, “mild” with grade 1, “moderate” with grade 2, and  
“severe/very severe” with grade 3/421,24; this was consistent 
with a previously developed mapping algorithm.22,23
Statistical Analysis
Descriptive statistics were used to summarize patient 
characteristics, breast cancer diagnoses and treatments, 
adverse events, and patient- and clinician-reported 
symptom scores. Because clinicians were not always 
available to complete reports, only data points from 
days on which both the patient and the clinician re-
ported were included. The essential metric for our study 
was the maximum score for each symptom at any time 
during the measurement period (start to end of chem-
otherapy); this is the approach used in clinical trials 
when treatment toxicity is reported. The proportions of 
moderate, severe, or very severe patient-reported symp-
tom severity and interference were compared with the 
proportions of clinician-rated grade 2, 3, or 4 toxicity 
for all 17 symptoms combined and for each symptom 
individually.
We assessed agreement between patient- and cli-
nician-reported dichotomized maximum scores by 
reporting simple κ coefficients for each symptom.25 
Dichotomization was “low” for none or mild and 
“high” for moderate, severe, or very severe. A priori in-
terpretation of the κ statistic used standard rating cri-
teria26: <0.0, less than chance agreement; 0.01 to 0.20, 
slight agreement; 0.21 to 0.40, fair agreement; 0.41 to 
0.60, moderate agreement; 0.61 to 0.80, substantial 
agreement; and 0.81 to 0.99, almost perfect agreement. 
The same method was used to compare the patient- 
reported symptom “interference with things you usually 
like to do” with the clinician toxicity grade. Chi-square 
tests were conducted to investigate whether patient 
characteristics were associated with patient-clinician 




In a sample of 267 women, the median age was 58 years 
(range, 24-83  years), and 26% were nonwhite. Breast 
cancer was distributed across stages I, II, and III and 
TABLE 1. Study Participant Characteristics 
(n = 267)
Variable Value
Age, median (SD), y 58 (13)
Age, range, y 24-83
Race, No. (%)
Not white 70 (26)
White 197 (74)
Education, No. (%)
High school or less 38 (14)




Body mass index, mean (SD), kg/m2 30 (7)
Body mass index, range, kg/m2 17-65
Body mass index, No. (%)
Underweight (<18.5 kg/m2) 3 (1)
Normal (18.5 to <25 kg/m2) 72 (27)
Overweight (25 to <30 kg/m2) 83 (31)
Obese I (≥30 kg/m2) 109 (41)
Menopausal status at breast cancer diagnosis, No. (%)
Premenopausal 81 (31)
Postmenopausal 183 (69)













Anti-HER2 therapy, No. (%) 67 (25)










Abbreviations: AC-T, doxorubicin and cyclophosphamide followed or pre-
ceded by paclitaxel/Taxol; AC-TC, doxorubicin and cyclophosphamide plus 
paclitaxel and carboplatin; TC, docetaxel and cyclophosphamide with or 
without anti–human epithelial growth factor receptor 2 (HER2) therapy; TCH; 
docetaxel and carboplatin plus anti–human epithelial growth factor receptor 
2 (HER2) therapy.
aThree patients also received anti-HER2 therapy.
across 4 different common chemotherapy regimens 
(Table 1). A total of 1203 same-day paired reports were 
considered in our analysis, and the maximum symp-
tom score for each patient was the unit of analysis.  
For patients receiving doxorubicin and cyclophospha-
mide followed or preceded by paclitaxel/Taxol (AC-T) 
or doxorubicin and cyclophosphamide plus paclitaxel 
and carboplatin (AC-TC), the median number of 
Figure 1. Maximum severity score at any time during chemotherapy: patient and clinician scores.
reports was 6; for those receiving docetaxel and cyclo-
phosphamide (TC) with or without anti–human epi-
thelial growth factor receptor 2 (HER2) therapy, it was 
3; for those receiving docetaxel and carboplatin plus 
anti-HER2 therapy (TCH) it was 5; and for all regi-
mens combined, it was 4.
Patient and Clinician Symptom Severity Scores
In Figure 1, the proportions of patient-reported maxi-
mum severity scores ranging from none to severe/very 
severe and clinician toxicity grades ranging from 0 to 
3/4 are presented for individual symptoms. For example, 
patient- and clinician-rated percentages were 22% and 
8% for severe or very severe fatigue, 41% and 46% for 
moderate fatigue, 32% and 39% for mild fatigue, and 6% 
and 7% for none. This figure illustrates how the propor-
tions of patient-reported moderate and severe/very severe 
symptoms were consistently higher than the proportions 
of clinician-rated toxicity grades 2 and 3/4.
Figure 2 illustrates the percentages of patients who 
rated their symptom severity or interference as moderate, 
severe, or very severe and the percentages of clinicians 
who rated their toxicity grade 2, 3, or 4. For example, 
in the far right grouping, 46% of patients rated more 
than 4 symptoms as moderate or worse in severity; 34% 
of patients rated more than 4 symptoms as moderate or 
worse in interference; and 27% of patients were rated by 
their clinician as having more than 4 symptoms graded 2, 
3, or 4. In the far left group, 15% of patients rated none 
of their symptoms as moderate or worse in severity, 27% 
of patients rated symptom interference as moderate or 
worse, and 19% of patients had none of their symptoms 
graded by their clinicians as 2 or higher.
Agreement of Patient- and Clinician-Rated 
Symptom Severity
Table 2 shows the proportions of study participants for 
whom patients and clinicians agreed that symptom sever-
ity was low (none or mild) or high (moderate or severe/
very severe). The table also shows where clinician maxi-
mum severity scores were higher than patient scores (cli-
nician high/patient low) and where patient maximum 
scores were higher than clinician scores (patient high/
clinician low). For example, for constipation, there was 
patient-physician agreement on low symptom severity 
for 65% of patients, and there was agreement on high 
symptom severity for 11% of patients; however, for 3% 
of patients, the clinicians rated symptom severity higher 
than their patients, and in turn, 21% of patients rated 
their constipation severity higher than their clinicians did.
Overall, there was moderate agreement (κ = 0.413-
0.570) on symptom severity for 9 of 17 symptoms (53%), 
fair agreement on 7 symptoms (41%; κ = 0.220-0.378), 
and slight agreement on 1 symptom (6%; κ  =  0.188). 
In the lower half of Table  2, we report comparisons of 
patient-reported symptom interference with clinician- 
reported severity. Again, we find moderate agreement 
(κ  =  0.402-0.522) on 7 of 17 symptoms (41%), fair 
Figure 2. Patient-reported moderate, severe, or very severe symptom severity and interference and clinician-rated grade 2, 3, or 4 
toxicity (percentages of patients).
agreement on 9 symptoms (53%; κ = 0.247-0.398), and 
slight agreement on 1 symptom (6%; κ = 0.150). All κ 
estimates were statistically significant (P ≤ .05).
Variables Associated With Patient-Clinician 
Agreement on Symptom Severity Scores
With 3 levels of agreement (agree, clinician high/patient 
low, and patient high/clinician low), associations with 
patient characteristics were explored (Supporting Table 2). 
The highest number of statistically significant associa-
tions (signifying differences between patient and clinician 
scores) was seen for race with respect to nausea (P = .05), 
arthralgia (P  =  .04), peripheral neuropathy (P  =  .04), 
and dyspnea (P  =  .05). These differences are further 
elucidated in Figure 3, which shows that in 21% of non-
white patients and 10% of white patients, clinicians rated 
peripheral neuropathy severity low when patients rated 
it high (P = .04). However, the reverse is shown for nau-
sea, for which clinicians rated symptom severity low when 
patients rated it high in 15% of white patients and 12% 
of nonwhite patients (P = .05).
Similarly, Figure 3 presents significant differences 
by body mass index (BMI), with clinician severity 
scores for constipation lower than patient scores for pa-
tients with BMIs less than 25 kg/m2 (14%), BMIs of 25 
to 30 kg/m2 (35%), and BMIs of 30 kg/m2 or higher 
(17%; P  =  .003). BMI-related differences are also 
shown for edema (P = .005), with the rate of clinician 
TABLE 2. Agreement Between Patients and Clinicians: Maximum Symptom Severity and Interference Scores 
at Any Time During Treatment (n = 267)
Symptom
Agreement on Maximum Symptom Severity Score, %
κaAgree Low Agree High Clinician High, Patient Low Patient High, Clinician Low
Constipation 65 11 3 21 0.329
Diarrhea 62 14 4 21 0.378
Nausea 65 14 7 14 0.437
Vomiting 90 2 4 5 0.220
Mucositis, oral 74 10 5 12 0.447
Fatigue, lack of energy 31 48 7 14 0.570
Aching joints/arthralgia 60 17 5 18 0.455
Aching muscles/myalgia 62 13 6 20 0.363
Peripheral neuropathy 60 16 11 13 0.413
Anxiety 57 16 5 22 0.372
Feeling sad, unhappy/depression 73 10 2 15 0.444
Insomnia 43 27 5 25 0.416
Dyspnea/light-headedness 77 4 4 15 0.224
Abdominal pain 83 2 2 14 0.188
Edema, limbs 79 4 1 17 0.245
General pain 60 20 8 12 0.523
Hot flashes 66 16 8 11 0.513
Symptom
Agreement on Maximum Symptom Interference Score, %
κaAgree Low Agree High Clinician High, Patient Low Patient High, Clinician Low
Constipation 77 6 7 9 0.337
Diarrhea 70 11 6 13 0.426
Nausea 68 11 9 12 0.384
Vomiting 89 1 4 6 0.150
Mucositis, oral 80 6 9 6 0.348
Fatigue, lack of energy 32 44 11 13 0.522
Aching joints/arthralgia 64 14 9 14 0.402
Aching muscles/myalgia 68 12 7 14 0.406
Peripheral neuropathy 64 10 18 8 0.256
Anxiety 68 13 9 11 0.441
Feeling sad, unhappy/depression 79 8 4 9 0.506
Insomnia 52 21 12 16 0.398
Dyspnea/light-headedness 78 4 4 12 0.275
Abdominal pain 85 3 1 11 0.265
Edema, limbs 86 2 2 10 0.247
General pain 61 18 11 10 0.466
Hot flashes 71 8 16 5 0.311
Low is defined as none or mild for patient-reported symptoms and as grade 0 or 1 for clinician-rated toxicities; high is defined as moderate, severe, or very severe 
for patient-reported symptoms and as grade 2, 3, or 4 for clinician-rated toxicities. For κ interpretation, <0.0 is less than chance agreement, 0.01 to 0.20 is slight 
agreement, 0.21 to 0.40 is fair agreement, 0.41 to 0.60 is moderate agreement, 0.61 to 0.80 is substantial agreement, and 0.81 to 0.99 is almost perfect agreement.
aAll κ values were statistically significant (P ≤ .05).
underreporting increasing with increasing BMI levels. 
Regarding marital status, clinician severity scores for pe-
ripheral neuropathy were lower for unmarried patients 
(19%) than married patients (8%; P = .03). There were 
no significant differences for age, education, or meno-
pausal status.
DISCUSSION
Quality of life has been measured extensively in 
women with early breast cancer,27 but few studies have 
administered single-item symptom assessments related 
to specific treatment- or disease-related adverse events 
at frequent intervals during active treatment (which is 
an emerging standard for adverse event monitoring in 
clinical trials)8 or have compared same-day patient and 
clinician reporting of this information. In our sample of 
women with early breast cancer, toxicity scores for 17 
symptoms were collected longitudinally via single-item 
scales for patient-reported symptom severity and inter-
ference (PRO-CTCAE or PRSM) and clinician toxicity 
Figure 3. Patient (PT)-clinician (MD) congruence by race and body mass index (BMI).
grades (CTCAE). Patients completed their form before 
seeing their oncologist, and clinicians completed their 
form after the visit. Scoring reports were not shared be-
tween patients and clinicians. The analysis was limited 
to patient-clinician scores that were collected on the 
same day (“paired”).
Across all 17 symptoms, clinician toxicity grades 
were lower than patient-reported severity scores, as 
seen in the proportions of symptoms for which patients 
rated symptom severity high but clinicians rated tox-
icity low. This observation corroborates findings from 
an Italian study in women with early breast cancer that 
compared symptom questionnaires from patients at 2 
time points (using a translation of CTCAE into Italian) 
with toxicity grades that were extracted and interpreted 
from clinician notes by research staff nurses.28 In our 
study, we note higher congruence between patients and 
clinicians when symptoms severity was low and lower 
congruence when symptom severity was high; this is 
similar to what has been previously reported in other 
studies.29 This observation is especially problematic 
when patients report high symptom severity but their 
clinicians note low toxicity, as observed for insomnia 
in 25% of patients, for anxiety in 22% of patients, for 
constipation in 25% of patients, for diarrhea in 21% 
of patients, and for myalgia in 20% of patients. It was 
exceptional when clinicians rated symptom toxicity 
high when their patients rated it low, as observed for 
peripheral neuropathy in 11% of patients, for general 
pain and hot flashes in 8% of patients, and for fatigue 
in 7% of patients.
We investigated patient-reported scores for “inter-
ference with what you usually like to do” and found 
them to be substantially lower than patient-reported 
symptom severity. We also compared patient-reported 
interference with clinician toxicity scores to see whether 
this comparison yielded greater congruence, but it did 
not. In our final analysis of the data, we found that 
patient characteristics were by and large not associated 
with patient-clinician disagreement on severity scores. 
However, we did find that clinician underestimation of 
certain symptoms was greater in nonwhite patients than 
white patients. This finding warrants further research 
but also reflects the larger literature documenting ra-
cial disparities in patient-provider communication30-33 
as well as racial differences in symptom management 
experiences.34
We note that patients completed their form be-
fore seeing their oncologist. Clinicians completed their 
form after the visit but not always immediately after 
seeing the patient. It is possible that a substantial time 
lag (which we did not measure) between seeing the pa-
tient and completing the form may have affected a cli-
nician’s recall of the patient’s symptom severity. We also 
did not gather data on whether the clinician form was 
completed by an MD, nurse practitioner, or physician 
assistant and, therefore, did not analyze potential differ-
ences among clinicians.
Patient-centered care, which is crucial to 
high-quality health care,35 requires the inclusion of 
the patient’s assessment of treatment toxicity. It is im-
portant to understand when and how patient and clini-
cian perspectives diverge and for which symptoms and 
patient characteristics they diverge. Our study points 
to the potential for racial disparities in symptom assess-
ment by clinicians. The moderate or lower κ agreement 
across all 17 symptoms suggests challenges in effec-
tive patient-clinician communication about symptom 
experience across domains of symptom clusters (eg, 
psychoneurological, gastrointestinal, and hormonal).36 
Disagreement in scores tends to be at the high symptom 
severity end of the spectrum, with clinicians underesti-
mating severity. Continuous symptom monitoring from 
both patients and clinicians, from before chemotherapy 
(to establish the patient’s baseline)7 through the end of 
chemotherapy, provides an opportunity for early inter-
vention for symptoms for which there are pharmaceuti-
cal remedies (eg, anxiety, depression, and insomnia) or 
nonpharmacological remedies (eg, moderate exercise to 
mitigate fatigue37,38).
There is growing evidence that patients are will-
ing and able to complete PRO-CTCAE items during a 
treatment-related clinic visit and after treatment has been 
completed.39 Using nurses and nurse navigators, clinics 
could consider developing processes to record and review 
patient-reported symptoms and consult with the oncolo-
gist for real-time interventions to reduce symptom sever-
ity. These processes would likely improve the likelihood 
of treatment completion, potentially improve patient 
quality of life during chemotherapy to the extent that 
toxicities are effectively managed, and enhance overall 
satisfaction with care.11,40 Alternative payment models 
for oncology could facilitate the incorporation of patient- 
reported symptom assessment into quality metrics by pro-
viding reimbursement for these added responsibilities.
In conclusion, although clinician reporting of 
symptoms is common practice in oncology, there is sub-
optimal agreement with the gold standard of patient 
self-reporting, particularly for nonwhite patients. These 
data provide further evidence supporting the integration 
of patient-reported outcomes into cancer research and 
clinical practice to improve symptom monitoring and 
guide timely interventions. This, in turn, would enable 
the timely identification of symptoms for which there 
are evidence-based interventions. Our findings sup-
port attention to patient-clinician interactions that are 
 patient-centered and focus on quality of life as well as  
effective symptom management with particular attention 
paid to cultural sensitivity.32,41 Further research is needed 
to explore approaches to encouraging and enabling 
 patient-provider communication on symptom severity in 
ways that are actionable in real-world clinical practice.
FUNDING SUPPORT
This study was supported by the Breast Cancer Research Foundation (New 
York, New York), the Kay Yow Cancer Fund (Raleigh, North Carolina), 
and the University of North Carolina Lineberger Comprehensive Cancer 
Center/University Cancer Research Fund (Chapel Hill, North Carolina). 
The University of Texas MD Anderson Cancer Center is supported by the 
National Institutes of Health (grant P30 CA016672).
CONFLICT OF INTEREST DISCLOSURES 
William A. Wood reports grants from Genentech and Pfizer outside the 
submitted work. The other authors made no disclosures.
AUTHOR CONTRIBUTIONS
Kirsten A. Nyrop: Primary authorship (original draft and review/editing of 
the article), conceptualization, and project administration. Allison M. Deal: 
Statistical analysis conceptualization and oversight. Bryce B. Reeve: Editing 
of the article and critical appraisal of the content. Ethan Basch: Editing of 
the article and critical appraisal of the content. Yi Tang Chen: Statistical 
analysis. Ji Hye Park: Statistical analysis. Shlomit S. Shachar: Verification 
of the methods, editing of the article, and critical appraisal of the content. 
Lisa A. Carey: Editing of the article and critical appraisal of the content. 
Katherine E. Reeder-Hayes: Editing of the article and critical appraisal of 
the content. Elizabeth C. Dees: Editing of the article and critical appraisal 
of the content. Trevor A. Jolly: Editing of the article and critical appraisal 
of the content. Gretchen G. Kimmick: Editing of the article and critical 
appraisal of the content. Meghan S. Karuturi: Editing of the article and 
critical appraisal of the content. Raquel E. Reinbolt: Editing of the article 
and critical appraisal of the content. JoEllen C. Speca: Editing of the article 
and critical appraisal of the content. Jordan T. Lee: Data collection, edit-
ing of the article, and critical appraisal of the content. William A. Wood: 
Editing of the article and critical appraisal of the content. Hyman B. Muss: 
Senior authorship, contributions to the original draft and review/editing of 
the article, verification of the methods, and critical appraisal of the content.
REFERENCES
1. National Cancer Institute. Common Terminology Criteria for Adverse
Events (CTCAE) v5.0. https://ctep.cancer.gov/proto colDe velop ment/
elect ronic_appli catio ns/ctc.htm#ctc_50
2. Velikova G, Booth L, Smith AB, et al. Measuring quality of life in
routine oncology practice improves communication and patient well- 
being: a randomized controlled trial. J Clin Oncol. 2004;22:714-724.
3. Atkinson TM, Ryan SJ, Bennett AV, et al. The association between
clinician-based Common Terminology Criteria for Adverse Events
(CTCAE) and patient-reported outcomes (PRO): a systematic review.
Support Care Cancer. 2016;24:3669-3676.
4. Basch E, Reeve BB, Mitchell SA, et al. Development of the National
Cancer Institute’s Patient-Reported Outcomes Version of the Common 
Terminology Criteria for Adverse Events (PRO-CTCAE). J Natl Cancer 
Inst. 2014;106:dju244.
5. Dueck AC, Mendoza TR, Mitchell SA, et al. Validity and reliability of
the US National Cancer Institute’s Patient-Reported Outcomes Version 
of the Common Terminology Criteria for Adverse Events (PRO-
CTCAE). JAMA Oncol. 2015;1:1051-1059.
6. Kluetz PG, Kanapuru B, Lemery S, et al. Informing the tolerability
of cancer treatments using patient-reported outcome measures: sum-
mary of an FDA and Critical Path Institute Workshop. Value Health.
2018;21:742-747.
7. Pe M, Dorme L, Coens C, et al. Statistical analysis of patient- 
reported outcome data in randomised controlled trials of locally
 advanced and metastatic breast cancer: a systematic review. Lancet 
Oncol. 2018;19:e459-e469.
8. Basch E, Bennett A, Pietanza MC. Use of patient-reported outcomes
to improve the predictive accuracy of clinician-reported adverse events. 
J Natl Cancer Inst. 2011;103:1808-1810.
9. Falchook AD, Green R, Knowles ME, et al. Comparison of patient- 
and practitioner-reported toxic effects associated with chemoradio-
therapy for head and neck cancer. JAMA Otolaryngol Head Neck Surg.
2016;142:517-523.
 10. Basch E, Iasonos A, McDonough T, et al. Patient versus clinician
symptom reporting using the National Cancer Institute Common
Terminology Criteria for Adverse Events: results of a question-
naire-based study. Lancet Oncol. 2006;7:903-909.
 11. Basch E, Jia X, Heller G, et al. Adverse symptom event reporting by pa-
tients vs clinicians: relationships with clinical outcomes. J Natl Cancer
Inst. 2009;101:1624-1632.
 12. Moon DH, Chera BS, Deal AM, et al. Clinician-observed and
 patient-reported toxicities and their association with poor tolerance to
therapy in older patients with head and neck or lung cancer treated
with curative radiotherapy. J Geriatr Oncol. 2019;10:42-47.
 13. Laugsand EA, Sprangers MA, Bjordal K, et al. Health care providers
underestimate symptom intensities of cancer patients: a multicenter
European study. Health Qual Life Outcomes. 2010;8:104.
 14. Fromme EK, Eilers KM, Mori M, et al. How accurate is clini-
cian  reporting of chemotherapy adverse effects? A comparison with
 patient-reported symptoms from the Quality-of-Life Questionnaire
C30. J Clin Oncol. 2004;22:3485-3490.
 15. Quinten C, Maringwa J, Gotay CC, et al. Patient self-reports of symp-
toms and clinician ratings as predictors of overall cancer survival. J Natl 
Cancer Inst. 2011;103:1851-1858.
 16. Cirillo M, Venturini M, Ciccarelli L, et al. Clinician versus nurse
symptom reporting using the National Cancer Institute–Common
Terminology Criteria for Adverse Events during chemotherapy: results
of a comparison based on patient’s self-reported questionnaire. Ann 
Oncol. 2009;20:1929-1935.
 17. Nyrop KA, Deal AM, Shachar SS, et al. Patient-reported toxicities
during chemotherapy regimens in current clinical practice for early
breast cancer. Oncologist. 2019;24:762-771.
 18. Nyrop KA, Deal AM, Reeder-Hayes KE, et al. Patient and clinician- 
reported chemotherapy-induced peripheral neuropathy (CIPN) in early 
breast cancer: current clinical practice. Cancer. 2019;125:2945-2954.
 19. Stover A, Irwin DE, Chen RC, et al. Integrating patient-reported
outcome measures into routine cancer care: cancer patients’ and cli-
nicians’ perceptions of acceptability and value. EGEMS (Wash DC).
2015;3:1169.
 20. Hay JL, Atkinson TM, Reeve BB, et al. Cognitive interviewing of the
US National Cancer Institute’s Patient-Reported Outcomes Version
of the Common Terminology Criteria for Adverse Events (PRO-
CTCAE). Qual Life Res. 2014;23:257-269.
 21. Atkinson TM, Hay JL, Dueck AC, et al. What do “none,” “mild,”
“moderate,” “severe,” and “very severe” mean to patients with cancer?
Content validity of PRO-CTCAE response scales. J Pain Symptom
Manage. 2018;55:e3-e6.
 22. Basch E, Becker C, Rogak LJ, et al. Development of a composite scor-
ing algorithm for the National Cancer Institute’s Patient-Reported
Outcomes Version of the Common Terminology Criteria for Adverse
Events (PRO-CTCAE). Paper presented at: 26th Annual Meeting of
the International Society for Quality of Life Research; October 20-23,
2019; San Diego, CA.
 23. Basch E, Rogak LJ, Dueck AC. Methods for implementing and report-
ing patient-reported outcome (PRO) measures of symptomatic adverse 
events in cancer clinical trials. Clin Ther. 2016;38:821-830.
 24. Basch E, Artz D, Dulko D, et al. Patient online self-reporting of toxic-
ity symptoms during chemotherapy. J Clin Oncol. 2005;23:3552-3561.
 25. Altman DG. Practical Statistics for Medical Research. Chapman and
Hall; 1991.
 26. Landis JR, Koch GG. The measurement of observer agreement for cat-
egorical data. Biometrics. 1977;33:159-174.
 27. Lemieux J, Goodwin PJ, Bordeleau LJ, et al. Quality-of-life measure-
ment in randomized clinical trials in breast cancer: an updated system-
atic review (2001-2009). J Natl Cancer Inst. 2011;103:178-231.
 28. Montemurro F, Mittica G, Cagnazzo C, et al. Self-evaluation of adju-
vant chemotherapy-related adverse effects by patients with breast can-
cer. JAMA Oncol. 2016;2:445-452.
 29. Atkinson TM, Reeve BB, Dueck AC, et al. Application of a Bayesian
graded response model to characterize areas of disagreement between
clinician and patient grading of symptomatic adverse events. J Patient
Rep Outcomes. 2018;2:56.
 30. Palmer NR, Kent EE, Forsythe LP, et al. Racial and ethnic dispari-
ties in patient-provider communication, quality-of-care ratings, and
patient activation among long-term cancer survivors. J Clin Oncol. 
2014;32:4087-4094.
 31. Royak-Schaler R, Passmore SR, Gadalla S, et al. Exploring patient- 
physician communication in breast cancer care for African American
women following primary treatment. Oncol Nurs Forum. 2008;35:836-843.
 32. Gonzales FA, Sangaramoorthy M, Dwyer LA, et al. Patient-clinician
interactions and disparities in breast cancer care: the Equality in Breast
Cancer Care Study. J Cancer Surviv. 2019;13:968-980.
 33. Robertson-Jones TA, Tissue MM, Connolly M, Gallups SF, Bender
CM, Rosenzweig MQ. Exploring racial differences in patient
centeredness of care (PCC) during breast cancer (BC) chemotherapy 
clinical visits. J Racial Ethn Health Disparities. 2019;6:94-100.
 34. Samuel CA, Schaal J, Robertson L, et al. Racial differences in symptom 
management experiences during breast cancer treatment. Support Care
Cancer. 2018;26:1425-1435.
 35. Institute of Medicine Committee on Quality of Health Care in
America. Crossing the Chasm: A New Health System for the 21st
Century. National Academy Press; 2001.
 36. Kim HJ, Barsevick AM, Tulman L, et al. Treatment-related symptom
clusters in breast cancer: a secondary analysis. J Pain Symptom Manage.
2008;36:468-479.
 37. Brown JC, Huedo-Medina TB, Pescatello LS, et al. Efficacy of exer-
cise interventions in modulating cancer-related fatigue among adult
cancer survivors: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 
2011;20:123-133.
 38. Cramp F, Byron-Daniel J. Exercise for the management of cancer- 
related fatigue in adults. Cochrane Database Syst Rev. 2012;11:
CD006145.
 39. Basch E, Pugh SL, Dueck AC, et al. Feasibility of patient reporting
of symptomatic adverse events via the Patient-Reported Outcomes
Version of the Common Terminology Criteria for Adverse Events
(PRO-CTCAE) in a Chemoradiotherapy Cooperative Group multi-
center clinical trial. Int J Radiat Oncol Biol Phys. 2017;98:409-418.
 40. Neugut AI, Hillyer GC, Kushi LH, et al. A prospective cohort study of 
early discontinuation of adjuvant chemotherapy in women with breast
cancer: the Breast Cancer Quality of Care Study (BQUAL). Breast 
Cancer Res Treat. 2016;158:127-138.
 41. Check DK, Chawla N, Kwan ML, et al. Understanding racial/eth-
nic differences in breast cancer–related physical well-being: the role
of patient-provider interactions. Breast Cancer Res Treat. 2018;170:
593-603.
